{"schema_version":"1.0","type":"article","title":"羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？","url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.md","lang":"zh-Hant","date":"2026-07-25","publish_at":"2026-07-25T09:20:00+08:00","updated_at":"2026-07-25","category":"商業分析系列","topic":"商業分析系列","tags":["Roche","羅氏","Big Pharma","製藥巨頭","giredestrant","fenebrutinib","trontinemab","petrelintide","bexobrutideg","全福生技","BRIM Biotechnology","BD 授權","藥物研發","生技估值"],"summary":"羅氏 2025 年製藥銷售 476.69 億瑞士法郎，Ocrevus、Hemlibra 與 Vabysmo 已撐起約三分之一收入。真正值得追的不是 19 個新分子的總數，而是 giredestrant、fenebrutinib、減重、阿茲海默症與蛋白質降解資產能否沿既有臨床、診斷與商業通路準時接棒。","key_points":[],"facts":[],"sections":["01｜轉型早已發生，收入表先說了","02｜最靠近終點的兩棒：giredestrant 與 fenebrutinib","03｜下一層選擇權：減重、阿茲海默症與 BTK 降解","04｜羅氏最值錢的，是省下重建市場的時間","05｜台灣看全福生技：眼科資產能不能接上成熟通路","結語｜羅氏最深的護城河，是不讓收入斷棒","參考資料","免責聲明"],"references":[{"title":"[Roche","source":"2025 年全年業績]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-01-29"},{"title":"[Roche","source":"Giredestrant 早期乳癌 NDA 獲 FDA 優先審查]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-06-02"},{"title":"[Roche","source":"Giredestrant 晚期乳癌 NDA 獲 FDA 受理]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-02-20"},{"title":"[Roche","source":"Fenebrutinib 第三個關鍵三期達主要終點]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-03-02"},{"title":"[Roche","source":"Fenebrutinib 四月完整三期與安全性資料]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-04-21c"},{"title":"[Roche","source":"與 Nurix 合作開發 Bexobrutideg]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-06-08"},{"title":"[Roche","source":"Petrelintide 合作交易條件]","date":"","url":"https://www.roche.com/media/releases/med-cor-2025-03-12"},{"title":"[Roche","source":"Petrelintide 二期結果]","date":"","url":"https://www.roche.com/media/releases/med-cor-2026-03-05"},{"title":"[Roche","source":"2026 ADA 減重管線更新]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-06-01"},{"title":"[Roche","source":"2026 AAIC 阿茲海默症藥品與診斷更新]","date":"","url":"https://www.roche.com/investors/updates/inv-update-2026-07-07"},{"title":"[Roche","source":"2025 Pharma Day 管線與 2030 上市潛力]","date":"","url":"https://assets.roche.com/f/176343/x/059c686d27/20250922_pharma-day-2025_vf_online.pdf"},{"title":"[Roche","source":"藥品研發管線]","date":"","url":"https://www.roche.com/solutions/pipeline"},{"title":"[全福生技","source":"公司與研發模式]","date":"","url":"https://www.brimbiotech.com/en/"},{"title":"[全福生技","source":"研發里程碑]","date":"","url":"https://www.brimbiotech.com/about-us/milestone"}],"images":[{"alt":"羅氏成熟產品把臨床試驗與商業通路交給下一代藥物","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-01-zh.webp"},{"alt":"羅氏以近端申報、中段三期與遠端新選擇權構成三層接棒架構","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-02-zh.webp"},{"alt":"羅氏把臨床試驗、診斷、醫師網路與商業通路重複用在六個疾病版圖","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-04-zh.webp"},{"alt":"全福生技四項眼科資產從證明、授權到放大的接棒考題","url":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-03-zh.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/cover-zh.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-25）。羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？。https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-25-roche-19-molecule-succession-engine-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}